Cargando…

High levels of TNFα in patients with COVID-19 refractory to tocilizumab

Detalles Bibliográficos
Autores principales:	Danlos, F.X., Ackermann, F., Rohmer, J., Roumier, M., Marabelle, A., Michot, J.M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Published by Elsevier Ltd. 2021
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7980142/ https://www.ncbi.nlm.nih.gov/pubmed/33848711 http://dx.doi.org/10.1016/j.ejca.2021.01.056

Ejemplares similares

Tocilizumab, an anti-IL-6 receptor antibody, to treat COVID-19-related respiratory failure: a case report
por: Michot, J.-M., et al.
Publicado: (2020)

1694P Discovery of circulating biomarkers in COVID-19 patients undergoing anti-IL6R immunotherapy
por: Michot, J-M., et al.
Publicado: (2020)

Tocilizumab administration in a refractory case of COVID-19
por: Dastan, Farzaneh, et al.
Publicado: (2020)

TNF-α Levels in Respiratory Samples Are Associated with SARS-CoV-2 Infection
por: Pereson, Matias J., et al.
Publicado: (2022)

TNF-α serum levels are elevated in women with clinically symptomatic uterine fibroids
por: Ciebiera, Michał, et al.
Publicado: (2018)

Tocilizumab in severe COVID-19
por: Lucio Liberato, Nicola, et al.
Publicado: (2020)

Interleukin 6 levels after tocilizumab administration in transplant recipients with COVID-19
por: Gade, Akhil R., et al.
Publicado: (2020)

High-flow nasal oxygen in severe COVID-19 pneumonia and tocilizumab
por: Mandal, M., et al.
Publicado: (2022)

Anakinra as a potential alternative in the treatment of severe acute respiratory infection associated with SARS-CoV-2 refractory to tocilizumab: comment()
por: Aomar-Millán, Ismael Francisco, et al.
Publicado: (2023)

Cytomegalovirus Viremia, Pneumonitis, and Tocilizumab Therapy
por: van Duin, David, et al.
Publicado: (2011)

Carbimazole inhibits TNF-α expression in Fat-induced hypothyroidism
por: Tripathi, Yamani Bhusan, et al.
Publicado: (2014)

Anti-TNF-α effects on anemia in rheumatoid and psoriatic arthritis
por: Corrado, Addolorata, et al.
Publicado: (2017)

Tocilizumab, Adipokines and Severe Complications of COVID-19
por: Fioravanti, Antonella, et al.
Publicado: (2020)

Could anakinra outmatch dexamethasone/tocilizumab in COVID-19?
por: Gupta, Rahul
Publicado: (2022)

Tocilizumab in a Child with Acute Leukoencephalopathy with Restricted Diffusion
por: Jaiswal, Anshul, et al.
Publicado: (2023)

Effect of tocilizumab versus standard of care in adults hospitalized with moderate-severe COVID-19 pneumonia
por: Aomar-Millán, Ismael F., et al.
Publicado: (2022)

Authors’ Reply to: Tocilizumab, Adipokines and Severe Complications of COVID-19
por: Liu, Bin, et al.
Publicado: (2020)

TNF-α-308 G/A Polymorphism in Egyptian Budd-Chiari Syndrome Patients
por: Eğin, Yonca, et al.
Publicado: (2012)

Comment on ‘Histopathologic evaluation of liver metastases from colorectal cancer in patients treated with FOLFOXIRI plus bevacizumab'
por: Bibeau, F, et al.
Publicado: (2013)

Rationale and evidence on the use of tocilizumab in COVID-19: A systematic review. Authors’ reply
por: Cortegiani, A., et al.
Publicado: (2021)

Effective treatment of severe acute pancreatitis and COVID-19 pneumonia with tocilizumab
por: Zielecki, Piotr, et al.
Publicado: (2020)

Tocilizumab as a promising agent against COVID-19: Issues and challenges
por: Dastan, Farzaneh, et al.
Publicado: (2021)

Anakinra or tocilizumab for prevention of COVID-19 death? A big dilemma
por: Patoulias, Dimitrios, et al.
Publicado: (2021)

Comparison of the risk of heart failure in psoriasis patients using anti‐TNF α inhibitors and ustekinumab
por: Han, Ju Hee, et al.
Publicado: (2022)

Can anti-TNFα Antibodies Affect SARS-CoV-2 Disease Outcomes?
por: Khazdair, Mohammad Reza
Publicado: (2022)

A neurology department at a tertiary-level hospital during the COVID-19 pandemic()
por: Grandas, F., et al.
Publicado: (2020)

Tocilizumab-induced granulomatous vasculitis and cutaneous actinomycosis in a patient with rheumatoid arthritis
por: Ziandarska, Justyna, et al.
Publicado: (2022)

Risk of hepatitis B reactivation following baricitinib or tocilizumab for treatment of COVID-19
por: Foo, Hong, et al.
Publicado: (2023)

Severe COVID-19 in patients with hematological cancers presenting with viremia
por: Michot, J.M., et al.
Publicado: (2021)

Tocilizumab for Severe Worsening COVID-19 Pneumonia: a Propensity Score Analysis
por: Roumier, Mathilde, et al.
Publicado: (2020)

Unique obstacles to establishing thyroid cancer registries
por: Pearce, Elizabeth N., et al.
Publicado: (2016)

Interleukin-6 blockade with tocilizumab in COVID-19: Does it live up to its hype?
por: Kow, C.S., et al.
Publicado: (2021)

Late Post-Coronavirus Disease 2019 Inflammatory Syndrome: A Case Experience with Tocilizumab
por: Tabarsi, Payam, et al.
Publicado: (2021)

Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis – Author’s reply
por: Kashour, Tarek, et al.
Publicado: (2021)

Tocilizumab for refractory severe immune checkpoint inhibitor-associated myocarditis
por: Doms, J., et al.
Publicado: (2020)

Autochthonous Leishmania siamensis in Horse, Florida, USA
por: Reuss, Sarah M., et al.
Publicado: (2012)

Nonengraftment donor lymphocyte infusions for refractory acute myeloid leukemia
por: Reagan, J L, et al.
Publicado: (2015)

Raman spectroscopic cellomics for the detection of SARS‐CoV‐2‐associated neutrophil activation after TNF‐α stimulation
por: Pistiki, Aikaterini, et al.
Publicado: (2022)

A phase II trial protocol of Tocilizumab in anti-TNF refractory patients with JIA-associated uveitis (the APTITUDE trial)
por: Ramanan, Athimalaipet V., et al.
Publicado: (2018)

Efficacy and safety of tocilizumab in hospitalized COVID-19 patients: A systematic review and meta-analysis
por: Luo, Lili, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_8b5b48sm84qp6iq1p1t56ac2n8